Clusterin silencing inhibits proliferation and reduces invasion in human laryngeal squamous carcinoma cells

World Journal of Surgical Oncology

Lin Zhang¹  Zimin Liu²  Quancai Su¹  Weiyan Cao³  Qianjin Wang⁴ 

[1] Department of Anesthesiology, the Affiliated Hospital of Qingdao University, Qingdao 266003, China;Department of Ontology, the Affiliated Hospital of Qingdao University, Qingdao 266003, China;Department of Obstetrics, Qingdao Central Hospital, Qingdao 266012, China;Department of Otolaryngology, Ju-nan County People’s Hospital, Ju-nan, Linyi 276600, China

关键词: Gene treatment;    Invasion;    Apoptosis;    Proliferation;    Clusterin;    Laryngeal squamous carcinoma;   

Others  :  819709
DOI  :  10.1186/1477-7819-12-124

 received in 2014-03-03, accepted in 2014-04-07,  发布年份 2014

【 摘 要 】

Background

Clusterin is, in its major form, a secreted heterodimeric disulfide-linked glycoprotein (sCLU), which plays important roles in cell survival and death. In laryngeal squamous cell carcinomas (LSCC), sCLU is up-regulated and its expression is related to the invasiveness of these tumors. The purpose of this study was to explore the inhibiting role of sCLU gene silence in the invasive ability and growth of Hep-2 human laryngeal squamous carcinoma cells (Hep-2) by transfection of short hairpin RNA expression plasmids against sCLU (sCLU-shRNA) (in vivo) or small interference RNA (sCLU-siRNA) (in vitro).

Methods

sCLU-siRNA and the control siRNA were transfected into Hep-2 cells using Lipofectamine 2000. RT-PCR and Western blot were used to detect the effect of siRNA transfection on sCLU mRNA and sCLU protein expression. The invasive activity of sCLU-siRNA-transfected Hep-2 cells was measured with the modified Boyden chamber assay and wound healing assay. The effects of sCLU-siRNA on cell proliferation were evaluated by MTT assay. Apoptosis was measured by Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) double-staining methods. We next evaluated the effects of sCLU silencing by sCLU-shRNA transfection in vivo on tumor growth and metastatic properties to the lung. Terminal deoxytransferase-mediated dUTP nick end labeling (TUNEL) staining was used to observe the apoptosis in the xenografts.

Results

It showed that siRNA-mediated down-regulation of sCLU expression in Hep-2 cells significantly inhibited cell proliferation and promoted apoptosis in vitro. Furthermore, siRNA-mediated down-regulation of sCLU expression decreases in vitro cell migration and invasion ability. In vivo, the average volume of tumors in the sCLU-shRNA transfected group was significantly lower than in the control group (P <0.01), and the significant apoptosis detected with TUNEL was indicated in the sCLU-shRNA transfected groups (P <0.05). Significantly, we found that sCLU-shRNA could exert marked inhibition of the lung metastasis of Hep-2 cells in nude mice in vivo.

Conclusions

sCLU gene silence can inhibit invasion and growth of LSCC. sCLU may provide a potential therapeutic target against human LSCC.

【 授权许可】

   
2014 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 6.

【 参考文献 】

• [1]Genden EM, Ferlito A, Silver CE, Jacobson AS, Werner JA: Evolution of the management of laryngeal cancer. Oral Oncol 2007, 43:431-439.
• [2]Bettuzzi S, Hiipakka RA, Gilna P, Liao ST: Identification of an androgen-repressed mRNA in rat ventral prostate as coding for sulphated glycoprotein 2 by cDNA cloning and sequence analysis. Biochem J 1989, 257:293-296.
• [3]Lee C, Sensibar JA, Dudek SM, Hiipakka RA, Liao ST: Prostatic ductal system in rats: regional variation in morphological and functional activities. Biol Reprod 1990, 43:1079-1086.
• [4]Bi J, Guo AL, Lai YR, Li B, Zhong JM, Wu HQ, Xie Z, He YL, Lv ZL, Lau SH, Wang Q, Huang XH, Zhang LJ, Wen JM, Guan XY: Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays. Neoplasma 2010, 57:191-197.
• [5]Yang GF, Li XM, Xie D: Overexpression of clusterin in ovarian cancer is correlated with impaired survival. Int J Gynecol Cancer 2009, 19:1342-1346.
• [6]Yom CK, Woo HY, Min SY, Kang SY, Kim HS: Clusterin overexpression and relapse-free survival in breast cancer. Anticancer Res 2009, 29:3909-3912.
• [7]Hazzaa SM, Elashry OM, Afifi IK: Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder. Pathol Oncol Res 2010, 16:101-109.
• [8]Kevans D, Foley J, Tenniswood M, Sheahan K, Hyland J, O'Donoghue D, Mulcahy H, O'Sullivan J: High clusterin expression correlates with a poor outcome in stage II colorectal cancers. Cancer Epidemiol Biomarkers Prev 2009, 18:393-399.
• [9]Lau SH, Sham JS, Xie D, Tzang CH, Tang D, Ma N, Hu L, Wang Y, Wen JM, Xiao G, Zhang WM, Lau GK, Yang M, Guan XY: Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 2006, 25:1242-1250.
• [10]Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C: Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 1997, 3:1707-1711.
• [11]Redondo M, Esteban F, González-Moles MA, Delgado-Rodríguez M, Nevado M, Torres-Muñoz JE, Tellez T, Villar E, Morell M, Petito CK: Expression of the antiapoptotic proteins clusterin and bcl-2 in laryngeal squamous cell carcinomas. Tumour Biol 2006, 27:195-200.
• [12]Miyake H, Gleave ME, Arakawa S, Kamidono S, Hara I: Introducing the clusterin gene into human renal cell carcinoma cells enhances their metastatic potential. J Urol 2002, 167:2203-2208.
• [13]Niu Z, Li X, Hu B, Li R, Wang L, Wu L, Wang X: Small interfering RNA targeted to secretory clusterin blocks tumor growth, motility, and invasion in breast cancer. Acta Biochim Biophys Sin (Shanghai) 2012, 44:991-998.
• [14]Li J, Jia L, Zhao P, Jiang Y, Zhong S, Chen D: Stable knockdown of clusterin by vectorbased RNA interference in a human breast cancer cell line inhibits tumour cell invasion and metastasis. J Int Med Res 2012, 40:545-555.
• [15]Yan Y, Luo K, Zhang H, Chai W: RNA interference-mediated secretory clusterin gene silencing inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cells. Hepatogastroenterology 2013, 60:70-75.
• [16]Chou TY, Chen WC, Lee AC, Hung SM, Shih NY, Chen MY: Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway. Cell Signal 2009, 21:704-711.
• [17]Bettuzzi S, Davalli P, Davoli S, Chayka O, Rizzi F, Belloni L, Pellacani D, Fregni G, Astancolle S, Fassan M, Corti A, Baffa R, Sala A: Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread. Oncogene 2009, 28:4344-4352.
• [18]Miyake H, Nelson C, Rennie PS, Gleave ME: Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000, 60:170-176.
• [19]Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES: Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 2004, 64:1834-1842.
• [20]Wang Y, Wang X, Zhao H, Liang B, Du Q: Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression. J Chemother 2012, 24:348-357.
• [21]Sutton D, Kim S, Shuai X, Leskov K, Marques JT, Williams BR, Boothman DA, Gao J: Efficient suppression of secretory clusterin levels by polymer-siRNA nanocomplexes enhances ionizing radiation lethality in human MCF-7 breast cancer cells in vitro. Int J Nanomedicine 2006, 1:155-162.
• [22]Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
• [23]Aagaard L, Rossi JJ: RNAi therapeutics: principle sprospects and challenges. Adv Drug Deliv Rev 2007, 59:75-86.
• [24]Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, Albuquerque RJ: Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008, 452:591-597.
• [25]Novina CD, Sharp PA: The RNAi revolution. Nature 2004, 430:161-164.
• [26]Achenbach TV, Brunner B, Heermeier K: Oligonucleotide-based knockdown technologies: antisense versus RNA interference. Chembiochem 2003, 4:928-935.